Bristol-Myers Squibb Co (LTS:0R1F)
$ 59.4 -0.61 (-1.02%) Market Cap: 119.70 Bil Enterprise Value: 163.01 Bil PE Ratio: 0 PB Ratio: 6.98 GF Score: 82/100

Bristol-Myers Squibb Co at Cowen Health Care Conference Transcript

Mar 12, 2019 / 03:20PM GMT
Release Date Price: $50.88 (+0.45%)
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD and Senior Research Analyst

So good morning. And we're thrilled to have Bristol-Myers Squibb with us at the Cowen Conference once again this year. Representing the company is Giovanni Caforio, who is Chairman and CEO; Tom Lynch, who's Executive Vice President and Chief Scientific Officer; Charlie Bancroft, who's Executive Vice President and CFO; and Chris Boerner, who is Executive Vice President and Chief Commercial Officer.

I mean, clearly, many investors continue to ponder the idea of Bristol-Myers Squibb acquiring Celgene. And 2 questions that we at Cowen have gotten consistently are, first, the merits of the transaction; and secondly, this notion of serial acquisitions, wouldn't have that been a better idea? And our response is there are clearly examples where 2 companies have come together and proven to be a stronger company as a result. I just think we need to all really give some thought to the fact that maybe Giovanni is absolutely right when he says this is a transformative acquisition done from a position of strength

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot